This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


H. Lundbeck A/S

Drug Names(s): SGS518, LY483518, AE58054, Idalopirdine, Lu AE58054

Description: Lu AE58054 is a potent and selective 5-HT6 receptor antagonist. The 5-HT6 receptor is primarily found in areas of the brain involved in cognition. Preclinical data suggests that the 5-HT6 receptor is found mainly in the central nervous system with little or no expression in peripheral tissues, which may result in greater drug selectivity with fewer side effects. Some areas the 5-HT6 receptor is found in are important for learning and memory. In preclinical models, blockade of the receptor improves cognitive function, and also reduces signs thought to reflect anxiety and depression. Blockade is accompanied by enhancement of cholinergic, glutamatergic, noradrenergic, and dopaminergic neurotransmission, together with learning-associated neuronal remodeling. The receptor may also be involved in food intake.

Deal Structure: Saegis and Eli Lilly
In October 2002, Saegis Pharmaceuticals licensed from Eli Lilly a preclinical compound (SGS518) to be developed for the treatment of cognitive impairment. Under the terms of an exclusive license, Saegis will be responsible for filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and for the design and execution of a clinical development program to demonstrate the human safety and efficacy of the compound for enhancement of cognition. The agreement also provides Lilly with an option to buy back thecompound following the completion of the Phase II clinical trial.

Lundbeck acquired the global rights to Lu AE58054 in connection with the acquisition of Saegis Pharmaceuticals in early 2007.

Lundbeck and Otsuka
In March 2013, H. Lundbeck and Otsuka entered into a license and development agreement for Lu AE58054. Under the terms of the agreement, Lundbeck will grant Otsuka co-development and...See full deal structure in Biomedtracker

Partners: Eli Lilly & Company Otsuka Holdings Co., Ltd.

Idalopirdine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug